Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. (Q33942782)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. |
scientific article |
Statements
Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis (English)
Michael W Konstan
Jeffrey S Wagener
Stefanie J Millar
Joan R Jacobs
Ashley Yegin
Wayne J Morgan
Scientific Advisory Group and Investigators and Coordinators of Epidemiologic Study of Cystic Fibrosis
24 March 2011
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference